Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Swindells

Showing results (81-90 of 170) with videos related to

Pageof 17
Sort By:
AIDS (London, England)|January 16, 2018
Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamideAnthony T Podany, Sara H Bares, Joshua Havens, et al.
AIDS (London, England)|November 21, 2007
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIVGrace A McComsey, Michelle A Kendall, Pablo Tebas, et al.
Neurology|October 19, 2018
Neural dynamics of selective attention deficits in HIV-associated neurocognitive disorderBrandon J Lew, Timothy J McDermott, Alex I Wiesman, et al.
BMC Infectious Diseases|April 12, 2005
Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimensSusan Swindells, Calvin J Cohen, Daniel S Berger, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 18, 2019
Evidence From a Multistate Cohort: Enrollment in Affordable Care Act Qualified Health Plans' Association With Viral SuppressionKathleen A McManus, Bianca Christensen, V Peter Nagraj, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 12, 2025
Preventing multidrug resistant tuberculosis: the dawn of a new eraGavin J Churchyard, Susan Swindells, Amita Gupta, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 21, 2007
Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trialBruce R Schackman, Callie A Scott, Paul E Sax, et al.
The Lancet. Microbe|April 9, 2021
Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trialAndreas Diacon, Sachiko Miyahara, Rodney Dawson, et al.
Ebiomedicine|October 25, 2020
The age-related trajectory of visual attention neural function is altered in adults living with HIV: A cross-sectional MEG studyYasra Arif, Alex I Wiesman, Jennifer O'Neill, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 26, 2013
Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot studyBabafemi Taiwo, Edward P Acosta, Patrick Ryscavage, et al.
Pageof 17

Showing results (81-90 of 170) with videos related to

Sort By:
Pageof 17
AIDS (London, England)|January 16, 2018
Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamideAnthony T Podany, Sara H Bares, Joshua Havens, et al.
AIDS (London, England)|November 21, 2007
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIVGrace A McComsey, Michelle A Kendall, Pablo Tebas, et al.
Neurology|October 19, 2018
Neural dynamics of selective attention deficits in HIV-associated neurocognitive disorderBrandon J Lew, Timothy J McDermott, Alex I Wiesman, et al.
BMC Infectious Diseases|April 12, 2005
Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimensSusan Swindells, Calvin J Cohen, Daniel S Berger, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 18, 2019
Evidence From a Multistate Cohort: Enrollment in Affordable Care Act Qualified Health Plans' Association With Viral SuppressionKathleen A McManus, Bianca Christensen, V Peter Nagraj, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 12, 2025
Preventing multidrug resistant tuberculosis: the dawn of a new eraGavin J Churchyard, Susan Swindells, Amita Gupta, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 21, 2007
Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trialBruce R Schackman, Callie A Scott, Paul E Sax, et al.
The Lancet. Microbe|April 9, 2021
Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trialAndreas Diacon, Sachiko Miyahara, Rodney Dawson, et al.
Ebiomedicine|October 25, 2020
The age-related trajectory of visual attention neural function is altered in adults living with HIV: A cross-sectional MEG studyYasra Arif, Alex I Wiesman, Jennifer O'Neill, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 26, 2013
Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot studyBabafemi Taiwo, Edward P Acosta, Patrick Ryscavage, et al.
Pageof 17